Publicaciones en colaboración con investigadores/as de Hospital Universitario Central de Asturias (145)

2024

  1. Characterization of the molecular composition and in vitro regenerative capacity of platelet-based bioproducts and related subfractions

    Acta Biomaterialia, Vol. 177, pp. 132-147

  2. Next-generation sequencing reveals that miR-16-5p, miR-19a-3p, miR-451a, and miR-25-3p cargo in plasma extracellular vesicles differentiates sedentary young males from athletes

    European Journal of Sport Science

  3. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

2023

  1. BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia

    Cancer Immunology, Immunotherapy, Vol. 72, Núm. 7, pp. 2529-2539

  2. Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy

    Molecular Cancer, Vol. 22, Núm. 1

  3. Chemo-Immunotherapy: A New Trend in Cancer Treatment

    Cancers, Vol. 15, Núm. 11

  4. Immunoglobulin-like transcript 2 blockade restores antitumor immune responses in glioblastoma

    Cancer Science, Vol. 114, Núm. 1, pp. 48-62

  5. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma

    Annals of Hematology, Vol. 102, Núm. 2, pp. 429-437

  6. Palladium nanoclusters as a label to determine GFAP in human serum from donors with stroke by bimodal detection: inductively coupled plasma-mass spectrometry and linear sweep voltammetry

    Microchimica Acta, Vol. 190, Núm. 12

  7. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients

    Haematologica, Vol. 108, Núm. 10, pp. 2753-2763

2022

  1. A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research

  2. Clinical Response After Treatment of Knee Osteoarthritis With a Standardized, Closed-System, Low-Cost Platelet-Rich Plasma Product: 1-Year Outcomes

    Orthopaedic Journal of Sports Medicine, Vol. 10, Núm. 3

  3. Nanozyme-Based Lateral Flow Immunoassay (LFIA) for Extracellular Vesicle Detection

    Biosensors, Vol. 12, Núm. 7

  4. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 9, pp. e844-e852

  5. RICORS2040: The need for collaborative research in chronic kidney disease

    Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387

  6. Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM)

    Leukemia and Lymphoma, Vol. 63, Núm. 14, pp. 3438-3447

2021

  1. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice

    Human Vaccines and Immunotherapeutics, Vol. 17, Núm. 11, pp. 4144-4154

  2. Btla/hvem axis induces nk cell immunosuppression and poor outcome in chronic lymphocytic leukemia

    Cancers, Vol. 13, Núm. 8

  3. Checkpoint inhibition in the fight against cancer: NK cells have some to say in it

    Successes and Challenges of NK Immunotherapy: Breaking Tolerance to Cancer Resistance (Elsevier), pp. 267-304

  4. Clinical management of hypertension, inflammation and thrombosis in hospitalized covid‐19 patients: Impact on survival and concerns

    Journal of Clinical Medicine, Vol. 10, Núm. 5, pp. 1-16